Related Experiment Video

Updated: May 26, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

[The kidney: target for blood glucose-lowering therapy]

Edwin Duijzer1, Manon Zwakenberg, Hiddo J Lambers Heerspink

  • 1Universitair Medisch Centrum Groningen, afd. Klinische Farmacologie, Groningen, the Netherlands.

Nederlands Tijdschrift Voor Geneeskunde
|December 14, 2011
PubMed

Insights

Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose and HbA1c in type 2 diabetes. These drugs also reduce blood pressure and body weight, offering potential new treatment strategies.

Area of Science:

  • Endocrinology
  • Nephrology
  • Pharmacology

Background:

  • Diabetes mellitus involves dysregulated glucose metabolism, increasing risks of vascular complications.
  • Many patients with diabetes do not achieve target blood glucose, blood pressure, or cardiovascular risk factor levels.
  • Novel therapeutic strategies are needed for improved diabetes management.

Purpose of the Study:

  • To evaluate the role of sodium-dependent glucose cotransporter 2 (SGLT2) in glucose regulation.
  • To assess the efficacy of SGLT2 inhibition as a treatment for type 2 diabetes mellitus.
  • To explore the broader metabolic and cardiovascular effects of SGLT2 inhibitors.

Main Methods:

  • Investigated the function of SGLT2 in the kidney's proximal tubule.
  • Examined the impact of SGLT2 inhibition on urinary glucose excretion.
  • Analyzed changes in plasma glucose, HbA1c, blood pressure, and body weight following SGLT2 inhibition.

Main Results:

  • SGLT2 inhibition increases urinary glucose excretion, lowering plasma glucose and HbA1c levels.
  • SGLT2 inhibitors demonstrate reductions in blood pressure and body weight.
  • Observed positive trends in triglyceride concentrations with SGLT2 inhibition.

Conclusions:

  • Oral SGLT2 inhibitors show promise as a significant treatment option for type 2 diabetes mellitus.
  • Further long-term studies are required to confirm cardiovascular risk reduction and long-term safety.
  • The relationship between increased urinary glucose excretion and urogenital infections warrants additional investigation.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Introduction to Urinary System01:13

Introduction to Urinary System

The urinary system consists of two kidneys, two ureters, the urinary bladder, and the urethra.
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...